Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TCF4 | P15884 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950315 | 0.78 | MAPT (0.37) | MEN1KMT2AGSK3BALDH1A1HPGD | |
| SCHEMBL15698069 | 0.78 | HSP90AB1 (0.42) | MEN1KMT2AHTTALDH1A1TSHR | |
| SCHEMBL9532477 | 0.78 | GSK3B (0.32) | MEN1KMT2AGSK3BALDH1A1HPGD | |
| SCHEMBL4984920 | 0.76 | GSK3B (0.41) | MEN1KMT2AGSK3BALDH1A1HPGD | |
| SCHEMBL30132596 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2AHTTALDH1A1HPGD | |
| SCHEMBL20554715 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2AHTTALDH1A1HPGD | |
| SCHEMBL9278783 | 0.74 | MAPT (0.38) | MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL26607361 | 0.74 | MEN1 (0.38) | MEN1KMT2AGSK3BHTTALDH1A1 | |
| SCHEMBL9321567 | 0.73 | KMT2A (0.40) | MEN1KMT2AGSK3BHTTALDH1A1 | |
| SCHEMBL1312586 | 0.73 | GAA (0.32) | MEN1KMT2AALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8283362-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| EP-2332915-A1 | Beta2-adrenoceptor agonists | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20110034509-A1 | Beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD | 2011-02-10 | — | — | US | disclosed |
| US-7820694-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | CUENOUD BERNARD | 2010-02-04 | — | — | US | disclosed |
| US-7622483-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2009-11-24 | — | — | US | disclosed |
| EP-1183240-B1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-6878721-B1 | N-(partially hydrogenated fused carbocycle)-2-arylethylamine derivatives, e.g., 8-hydroxy-5-(1-hydroxy-2-(indan-2-ylamino)-ethyl)-1H-quinolin-2-one; treatment of obstructive or inflammatory | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| EP-1183240-A1 | BETA2-ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075114-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034509-A1 | Beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | MEN1 3910/4885KMT2A 4092/4885GSK3B 1535/4885 |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | MEN1 3721/4885KMT2A 4326/4885GSK3B 1349/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | MEN1 4161/4885KMT2A 3571/4885GSK3B 1272/4885 |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | MEN1 4809/4885KMT2A 4231/4885GSK3B 2066/4885 |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | MEN1 4809/4885KMT2A 4231/4885GSK3B 2066/4885 |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRB3 | MEN1 3579/4885KMT2A 4426/4885GSK3B 1364/4885 |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | MEN1 3910/4885KMT2A 4092/4885GSK3B 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.